CA2835913A1 - Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure - Google Patents

Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure Download PDF

Info

Publication number
CA2835913A1
CA2835913A1 CA2835913A CA2835913A CA2835913A1 CA 2835913 A1 CA2835913 A1 CA 2835913A1 CA 2835913 A CA2835913 A CA 2835913A CA 2835913 A CA2835913 A CA 2835913A CA 2835913 A1 CA2835913 A1 CA 2835913A1
Authority
CA
Canada
Prior art keywords
cathepsin
pulmonary hypertension
treatment
heart failure
ctsk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2835913A
Other languages
English (en)
French (fr)
Inventor
Stefan Golz
Martina Delbeck
Heinrich Meier
Andreas Geerts
Thomas MONDRITZKI
Hubert Trubel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CA2835913A1 publication Critical patent/CA2835913A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
CA2835913A 2011-05-16 2012-05-11 Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure Abandoned CA2835913A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166229.2 2011-05-16
EP11166229 2011-05-16
PCT/EP2012/058773 WO2012156311A1 (en) 2011-05-16 2012-05-11 Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure

Publications (1)

Publication Number Publication Date
CA2835913A1 true CA2835913A1 (en) 2012-11-22

Family

ID=46085031

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2835913A Abandoned CA2835913A1 (en) 2011-05-16 2012-05-11 Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure

Country Status (15)

Country Link
US (1) US9943522B2 (zh)
EP (1) EP2709602B1 (zh)
JP (1) JP6000340B2 (zh)
KR (1) KR20140034821A (zh)
CN (1) CN103687593B (zh)
AU (1) AU2012257779A1 (zh)
BR (1) BR112013029672A2 (zh)
CA (1) CA2835913A1 (zh)
ES (1) ES2648819T3 (zh)
IL (1) IL229312A0 (zh)
MX (1) MX2013013281A (zh)
RU (1) RU2013155509A (zh)
SG (1) SG194842A1 (zh)
WO (1) WO2012156311A1 (zh)
ZA (1) ZA201308391B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194842A1 (en) 2011-05-16 2013-12-30 Bayer Ip Gmbh Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
CN103381152A (zh) * 2013-02-05 2013-11-06 吉林省金梓源生物科技有限公司 杨梅素作为组织蛋白酶k抑制剂的用途
US11766467B2 (en) 2017-09-01 2023-09-26 University Of Wyoming Methods of treating wounds using cathepsin K inhibitors
US10758559B1 (en) 2017-09-01 2020-09-01 University Of Wyoming Targeting cathepsin K to facilitate wound healing
CN109864990B (zh) * 2017-12-05 2022-07-15 中国医学科学院药物研究所 巴利卡替在制备抗丝状病毒感染药物中的应用
CN110981937B (zh) * 2018-09-30 2021-11-12 北京和理咨询有限公司 Odn或衍生物的多肽偶合物及其制备方法和应用
WO2022072504A1 (en) * 2020-09-29 2022-04-07 Healion Bio, Inc. Methods and compositions for the treatment of viral diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1022276T3 (da) 1997-09-04 2003-09-29 Nippon Chemiphar Co Epoxysuccinamidderivater
HUP0104768A3 (en) 1998-12-23 2002-05-28 Smithkline Beecham Corp 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
AU774827B2 (en) 1999-03-15 2004-07-08 Axys Pharmaceuticals, Inc. N-cyanomethyl amides as protease inhibitors
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
EP1307203A4 (en) 2000-03-21 2005-08-17 Smithkline Beecham Corp PROTEINASE INHIBITOR
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20040009171A1 (en) 2001-10-18 2004-01-15 Genentech, Inc. Methods for the treatment of carcinoma
NZ534583A (en) * 2002-03-05 2006-11-30 Axys Pharm Inc Leucinamide derivatives suitable as cathepsin cysteine protease inhibitors
EP1532134B1 (fr) 2002-07-04 2008-06-04 Aventis Pharma S.A. Nouveaux derives acyl hydrazino du thiophene, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US20060020001A1 (en) * 2002-12-23 2006-01-26 Allan Shepard Use of cathepsin k inhibitors for the treatment of glaucoma
CN100506811C (zh) 2003-04-25 2009-07-01 日本化学医药株式会社 (2s,3s)-3-[[(1s)-1-异丁氧基甲基-3-甲基丁基]氨基甲酰基]环氧乙烷-2-甲酸盐
WO2006076797A1 (en) * 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and atherosclerosis
US20090005323A1 (en) * 2005-01-19 2009-01-01 Michael David Percival Cathepsin K Inhibitors and Obesity
CA2614070C (en) 2005-07-06 2014-03-25 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
ES2703274T3 (es) * 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
WO2010011605A2 (en) * 2008-07-21 2010-01-28 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
SG194842A1 (en) 2011-05-16 2013-12-30 Bayer Ip Gmbh Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure

Also Published As

Publication number Publication date
EP2709602B1 (en) 2017-08-23
SG194842A1 (en) 2013-12-30
BR112013029672A2 (pt) 2017-01-17
CN103687593B (zh) 2016-09-28
RU2013155509A (ru) 2015-06-27
AU2012257779A1 (en) 2013-11-28
ZA201308391B (en) 2015-02-25
IL229312A0 (en) 2014-01-30
WO2012156311A1 (en) 2012-11-22
KR20140034821A (ko) 2014-03-20
ES2648819T3 (es) 2018-01-08
CN103687593A (zh) 2014-03-26
MX2013013281A (es) 2013-12-06
JP6000340B2 (ja) 2016-09-28
JP2014518868A (ja) 2014-08-07
EP2709602A1 (en) 2014-03-26
US9943522B2 (en) 2018-04-17
US20140155383A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
US9943522B2 (en) Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
Haynes et al. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice
AU2002313700B2 (en) Method for reducing hypertension and heart failure
CN107530298B (zh) 利用酪氨酸激酶抑制剂的组合物和方法
JP2009509984A (ja) 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
US11229679B2 (en) Compositions for treating heart disease by inhibiting the action of mAKAPβ
JP2019506459A (ja) アルファ−１−アドレナリン受容体アゴニスト療法
TW201026684A (en) Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy
Zimmerman et al. Vasopressors and inotropes
JP2020510071A (ja) 特発性肺線維症の治療
AU2020259450A1 (en) Methods of treating hypertension with activators of Tie-2
Uechi et al. Evaluation of the renin-angiotensin system in cardiac tissues of cats with pressure-overload cardiac hypertrophy
US20090030065A1 (en) Use of Pde1c and Inhibitors Thereof
TW201311235A (zh) 組織蛋白酶ｋ抑制劑於治療及／或預防肺性高血壓及／或心衰竭之用途
US9339482B2 (en) Methods to treat dysregulated blood glucose disorders
JP2019514942A (ja) 心室リモデリングの予防及び／又は治療におけるカルパイン阻害剤
EP4225307A1 (en) Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
JP2022532763A (ja) Ｐｐ２ａアンカリングの阻害による心疾患の処置
Logan Overview: Recent Advances in the Treatment of Heart Failure: Patent Activity in 1992
SMCS et al. Canadian Cardiovascular Society (CCS) CCS180 Poster BASIC AND CLINICAL HYPERTENSION RESEARCH Sunday, October 24, 2010
TW201134484A (en) Therapeutic use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170503

FZDE Discontinued

Effective date: 20200831